Development Partners International (DPI), an investment firm focused on Africa with USD2.8 billion in assets under management including co-investments, and CDC Group (CDC), the UK’s development finance institution that will shortly be renamed British International Investment (BII), are leading an up to USD200 million second funding round in KELIX bio.
The funding will then be used by KLEIX to finance the acquisition of Pharmaceutical Institute (PHI).
PHI is a Moroccan-headquartered producer and distributor of generic and therapeutic pharmaceuticals.
The acquisition is subject to regulatory approvals in Morocco. It is expected to close in the first quarter of 2022.